The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma

British Journal of Haematology

Volumn 145, Issue 2, 2009, Pages 180-189

  Romagnoli, Mathilde ^a,b   Séveno, Céline ^a,b   Wuillème Toumi, Soraya ^a,b   Amiot, Martine ^a,b   Bataille, Régis ^a,b   Minvielle, Stéphane ^a,b   Barillé Nion, Sophie ^a,b  

^a INSERM   (France)

^b Nantes Atlantique Universités   (France)

Author keywords

Apoptosis; Bim; Myeloma; Survivin; Tumour growth

Indexed keywords

BH3 PROTEIN; BIM PROTEIN; INTERLEUKIN 6; PEPTIDES AND PROTEINS; PROTEIN BCL2L11; PROTEIN BIRC5; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CLONE CELLS; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MEMBRANE PROTEINS; MICE; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TUMOR ESCAPE;

EID: 63449129984     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07608.x     Document Type: Article

References (46)

1. Allen, S.M., Florell, S.R., Hanks, A.N., Alexander, A., Diedrich, M.J., Altieri, D.C. Grossman, D. (2003) Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumour progression. Cancer Research, 63, 567 572.
2. Altieri, D.C. (2008) Survivin, cancer networks and pathway-directed drug discovery. Nature Reviews Cancer, 8, 61 70.
3. Barillé, S., Bataille, R., Rapp, M.J., Harousseau, J.L. Amiot, M. (1999) Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation. Journal of Immunology, 163, 5723 5728.
4. Bellot, G., Cartron, P.F., Er, E., Oliver, L., Juin, P., Armstrong, L.C., Bornstein, P., Mihara, K., Manon, S. Vallette, F.M. (2007) TOM22, a core component of the mitochondria outer membrane protein translocation pore, is a mitochondrial receptor for the proapoptotic protein Bax. Cell Death and Differentiation, 14, 785 794.
5. Bergsagel, P.L. Kuehl, W.M. (2005) Molecular pathogenesis and a consequent classification of multiple myeloma. Journal of Clinical Oncology, 23, 6333 6338.
6. Billadeau, D., Jelinek, D.F., Shah, N., LeBien, T.W. Van Ness, B. (1995) Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6. Cancer Research, 55, 3640 3646.
7. Bouillet, P., Metcalf, D., Huang, D.C., Tarlinton, D.M., Kay, T.W., Köntgen, F., Adams, J.M. Strasser, A. (1999) Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science, 286, 1735 1738.
8. Decaux, O., Lodé, L., Magrangeas, F., Charbonnel, C., Gouraud, W., Jézéquel, P., Attal, M., Harousseau, J.L., Moreau, P., Bataille, R., Campion, L., Avet-Loiseau, H. Minvielle, S. (2008) Prediction of survival in multiple myeloma based on gene-expression profiles revealed cell cycle chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients. Journal of Clinical Oncology, 29, 4798 4805.
9. Del Gaizo Moore, V., Brown, J.R., Certo, M., Love, T.M., Novina, C.D. Letai, A. (2007) Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. Journal of Clinical Investigation, 117, 112 121.
10. Dijkers, P.F., Medema, R.H., Lammers, J.W., Koenderman, L. Coffer, P.J. (2000) Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Current Biology, 10, 1201 1204.
11. Dohi, T., Beltrami, E., Wall, N.R., Plescia, J. Altieri, D.C. (2004) Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. Journal of Clinical Investigation, 114, 1117 1127.
12. Dohi, T., Xia, F. Altieri, D.C. (2007) Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Molecular Cell, 27, 17 28.
13. Egle, A., Harris, A.W., Bouillet, P. Cory, S. (2004) Bim is a suppressor of Myc-induced mouse B cell leukemia. Proceedings of the National Academy of Sciences of the USA, 101, 6164 6169.
14. Ewings, K.E., Wiggins, C.M. Cook, S.J. (2007) Bim and the pro-survival Bcl-2 proteins: opposites attract, ERK repels. Cell Cycle, 6, 2236 2240.
15. Gomez-Bougie, P., Bataille, R. Amiot, M. (2004) The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells. European Journal of Immunology, 34, 3156 3164.
16. Gritsko, T., Williams, A., Turkson, J., Kaneko, S., Bowman, T., Huang, M., Nam, S., Eweis, I., Diaz, N., Sullivan, D., Yoder, S., Enkemann, S., Eschrich, S., Lee, J.H., Beam, C.A., Cheng, J., Minton, S., Muro-Cacho, C.A. Jove, R. (2006) Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clinical Cancer Research, 12, 11 19.
17. Ishikawa, H., Tsuyama, N., Abroun, S., Liu, S., Li, F.J., Taniguchi, O. Kawano, M.M. (2002) Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6. Blood, 9, 2172 2178.
18. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B.K., Tanabe, O. Tanaka, H. (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature, 332, 83 85.
19. Klein, B., Zhang, X.G., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M. Bataille, R. (1989) Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood, 73, 517 526.
20. Kuehl, W.M. Bergsagel, P.L. (2002) Multiple myeloma: evolving genetic events and host interactions. Nature Reviews Cancer, 2, 175 187.
21. Li, F., Ambrosini, G., Chu, E.Y., Plescia, J., Tognin, S., Marchisio, P.C. Altieri, D.C. (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature, 396, 580 584.
22. Magrangeas, F., Nasser, V., Avet-Loiseau, H., Loriod, L., Decaux, O., Granjeaud, S., Bertucci, F., Birnbaum, D., Nguyen, C., Harousseau, J.L., Bataille, R., Houlgatte, R. Minvielle, S. (2003) Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood, 101, 4998 5006.
23. Magrangeas, F., Lode, L., Wuilleme, S., Minvielle, S. Avet-Loiseau, H. (2005) Genetic heterogeneity in multiple myeloma. Leukemia, 19, 191 194.
24. Matsui, H., Asou, H. Inaba, T. (2007) Cytokines direct the regulation of Bim mRNA stability by heat-shock cognate protein 70. Molecular Cell, 25, 99 112.
25. Nakahara, T., Takeuchi, M., Kinoyama, I., Minematsu, T., Shirasuna, K., Matsuhisa, A., Kita, A., Tominaga, F., Yamanaka, K., Kudoh, M. Sasamata, M. (2007) YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumour xenografts. Cancer Research, 67, 8014 8021.
26. Petrocca, F., Visone, R., Onelli, M.R., Shah, M.H., Nicoloso, M.S., de Martino, I., Iliopoulos, D., Pilozzi, E., Liu, C.G., Negrini, M., Cavazzini, L., Volinia, S., Alder, H., Ruco, L.P., Baldassarre, G., Croce, C.M. Vecchione, A. (2008) E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell, 13, 272 286.
27. Pfaffl, M.W. (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research, 29, e45.
28. Plescia, J., Salz, W., Xia, F., Pennati, M., Zaffaroni, N., Daidone, M.G., Meli, M., Dohi, T., Fortugno, P., Nefedova, Y., Gabrilovich, D.I., Colombo, G. Altieri, D.C. (2005) Rational design of shepherdin, a novel anticancer agent. Cancer Cell, 7, 457 468.
29. Puthalakath, H., O'Reilly, L.A., Gunn, P., Lee, L., Kelly, P.N., Huntington, N.D., Hughes, P.D., Michalak, E.M., McKimm-Breschkin, J., Motoyama, N., Gotoh, T., Akira, S., Bouillet, P. Strasser, A. (2007) ER stress triggers apoptosis by activating BH3-only protein Bim. Cell, 129, 1337 1349.
30. Ramjaun, A.R., Tomlinson, S., Eddaoudi, A. Downward, J. (2007) Upregulation of two BH3-only proteins, Bmf and Bim, during TGF beta-induced apoptosis. Oncogene, 26, 970 981.
31. Rawat, R., Rainey, G.J., Thompson, C.D., Frazier-Jessen, M.R., Brown, R.T. Nordan, R.P. (2000) Constitutive activation of STAT3 is associated with the acquisition of an interleukin 6-independent phenotype by murine plasmacytomas and hybridomas. Blood, 96, 3514 3521.
32. Richardson, P., Mitsiades, C., Schlossman, R., Ghobrial, I., Hideshima, T., Chauhan, D., Munshi, N. Anderson, K. (2007) The treatment of relapsed and refractory multiple myeloma. Hematology American Society of Hematology Educational Program, 2007, 317 323.
33. Romagnoli, M., Trichet, V., David, C., Clément, M., Moreau, P., Bataille, R. Barillé-Nion, S. (2007) Significant impact of survivin on myeloma cell growth. Leukemia, 21, 1070 1078.
34. Ruchaud, S., Carmena, M. Earnshaw, W.C. (2007) Chromosomal passengers: conducting cell division. Nature Reviews Molecular Cell Biology, 8, 798 812.
35. Salz, W., Eisenberg, D., Plescia, J., Garlick, D.S., Weiss, R.M., Wu, X.R., Sun, T.T. Altieri, D.C. (2005) A survivin gene signature predicts aggressive tumour behavior. Cancer Research, 65, 3531 3534.
36. Shaughnessy, Jr., J.D., Zhan, F., Burington, B.E., Huang, Y., Colla, S., Hanamura, I., Stewart, J.P., Kordsmeier, B., Randolph, C., Williams, D.R., Xiao, Y., Xu, H., Epstein, J., Anaissie, E., Krishna, S.G., Cottler-Fox, M., Hollmig, K., Mohiuddin, A., Pineda-Roman, M., Tricot, G., van Rhee, F., Sawyer, J., Alsayed, Y., Walker, R., Zangari, M., Crowley, J. Barlogie, B. (2007) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood, 109, 2276 2284.
37. Sommer, K.W., Rodgarkia-Dara, C.J., Schreiner, C., Holzmann, K., Krupitza, G. Cerni, C. (2007) Oncogenic c-H-ras deregulates survivin expression: an improvement for survival. FEBS Letters, 581, 4921 4926.
38. Suzuki, A., Hayashida, M., Ito, T., Kawano, H., Nakano, T., Miura, M., Akahane, K. Shiraki, K. (2000) Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation. Oncogene, 19, 3225 3234.
39. Thomas, J., Liu, T., Cotter, M.A., Florell, S.R., Robinette, K., Hanks, A.N. Grossman, D. (2007) Melanocyte expression of survivin promotes development and metastasis of UV-induced melanoma in HGF-transgenic mice. Cancer Research, 67, 5172 5178.
40. Velculescu, V.E., Madden, S.L., Zhang, L., Lash, A.E., Yu, J., Rago, C., Lal, A., Wang, C.J., Beaudry, G.A., Ciriello, K.M., Cook, B.P., Dufault, M.R., Ferguson, A.T., Tong-Chuan, Y.G., Heiko, H.H., Hermeking, H., Hiraldo, S.K., Hwang, P.M., Lopez, M.A., Luderer, H.F., Mathews, B., Petroziello, J.M., Polyak, K., Zawel, L., Xiaoming, W.Z., Zhou, Z.W., Haluska, F.G., Jin Jen, J., Sukumar, S., Landes, G.M., Riggins, G.J., Vogelstein, B. Kinzler, K.M. (1999) Analysis of human transcriptomes. Nature Genetics, 23, 387 388.
41. Wuilleme-Toumi, S., Trichet, V., Gomez-Bougie, P., Gratas, C., Bataille, R. Amiot, M. (2007) Reciprocal protection of Mcl-1 and Bim from ubiquitin-proteasome degradation. Biochemical and Biophysical Research Communications, 361, 865 869.
42. Xiao, C., Srinivasan, L., Calado, D.P., Patterson, H.C., Zhang, B., Wang, J., Henderson, J.M., Kutok, J.L. Rajewsky, K. (2008) Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nature Immunology, 9, 405 414.
43. Youle, R.J. Strasser, A. (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nature Reviews Molecular Cell Biology, 9, 47 59.
44. Zantl, N., Weirich, G., Zall, H., Seiffert, B.M., Fischer, S.F., Kirschnek, S., Hartmann, C., Fritsch, R.M., Gillissen, B., Daniel, P.T. Häcker, G. (2007) Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance. Oncogene, 26, 7038 7048.
45. Zhan, F., Huang, Y., Colla, S., Stewart, J.P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., Anaissie, E., Hollmig, K., Pineda-Roman, M., Tricot, G., van Rhee, F., Walker, R., Zangari, M., Crowley, J., Barlogie, B. Shaughnessy, Jr., J.D. (2006) The molecular classification of multiple myeloma. Blood, 108, 2020.
46. Zhang, X.G., Gaillard, J.P., Robillard, N., Lu, Z.Y., Gu, Z.J., Jourdan, M., Boiron, J.M., Bataille, R. Klein, B. (1994) Reproducible obtaining of human myeloma cell lines as a model for tumour stem cell study in human multiple myeloma. Blood, 83, 3654 3663.